Charity aims to encourage the prioritization of sight loss in NHS

Article

More attention should be paid to dealing with sight loss, claims a new report created by ocular charity Visionary.

More attention should be paid to dealing with sight loss, claims a new report created by ocular charity Visionary.

The research is based on an evaluation of 68 Primary Care Trusts (PCTs) completed by the charity. The results revealed a significant difference in the level and quality of treatment administered across the UK.

Visionary is encouraging the NHS Commissioning Board to take action to ensure eye care is equally prioritized nationwide. The NHS initiative Action on Cataract aimed to perform 3200 cataract procedures per 100000 in patients over 65 years of age. However, the latest findings show that 11 PCTs in the UK are not reaching this target.

Angela Tinker, Chief Executive of Visionary, commented, "It is frightening that in the modern health service the reality is you could lose your sight despite there being effective treatments available. People should not be made to live with the devastating effects of sight loss or impairment simply because of where they live."

"At a local level we want to make sure systems are in place in the new NHS to help people get the right treatment fast. At the national level we want to ensure that the power is in place to redress the imbalance in the current postcode lottery to avoid unnecessary sight impairment and sight loss which seems inevitable in the current conditions."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.